

**UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF NEW YORK**

JOHN GAUQUIE, INDIVIDUALLY AND ON
BEHALF OF ALL OTHERS SIMILARLY
SITUATED,

Plaintiff,

v.

ALBANY MOLECULAR RESEARCH, INC.,
WILLIAM MARTH, and MICHAEL NOLAN,
Defendants.

Civil Action No. 14-cv-06637 (FB)
(SMG)

**NOTICE OF PENDENCY AND PROPOSED SETTLEMENT
OF CLASS ACTION AND FAIRNESS HEARING**

If you purchased the common stock of Albany Molecular Research, Inc. (“AMRI”) during the period from August 5, 2014 through November 5, 2014, inclusive, (the “Settlement Class Period”), you might be entitled to a payment from a class action settlement (the “Settlement”) as described in fuller detail in the Amended Stipulation of Settlement dated June 23, 2017 (the “Stipulation”).

A Federal Court authorized this Notice. This is not a solicitation from a lawyer.

The purpose of this Notice is to inform you of (a) the pendency of this class action (the “Action”), (b) the proposed settlement of the Action (the “Settlement”), and (c) the hearing to be held by the Court (the “Final Fairness Hearing”) to consider (i) whether the Settlement should be approved, (ii) the application of Lead Counsel for attorneys’ fees and expenses, and (iii) certain other matters. This Notice describes important rights you may have and what steps you must take if you wish to participate in the Settlement or wish to be excluded from the Settlement Class.

- The Settlement provides a total recovery of Two Million Eight Hundred Sixty Eight Thousand Dollars (\$2,868,000.00) in cash for the benefit of the Settlement Class described herein.
- The Settlement resolves a lawsuit alleging that AMRI and the individual defendants listed in the above caption (collectively, “Defendants”) violated federal securities laws by misrepresenting and/or omitting information regarding a power outage that occurred in late July 2014 at an AMRI manufacturing facility – claims that Defendants deny.
- **Your legal rights will be affected by this Action and this Settlement whether you act or do not act. Please read this Notice carefully.**

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT:	
SUBMIT A PROOF OF CLAIM FORM	The only way to get a payment.
EXCLUDE YOURSELF	You will get no payment. This is the only option that allows you to ever bring or maintain your own lawsuit against the Defendants and the other Released Persons, or to be part of another lawsuit, concerning the Released Claims.
OBJECT	Write to the Court about why you do not like the Settlement.
GO TO A HEARING	Ask to speak in Court about the Settlement.
DO NOTHING	You will get no payment, and you will give up rights.

- These rights and options—**and the deadlines to exercise them**—are explained in this Notice.
- The Court in charge of this case still has to decide whether to approve the Settlement. Payments will be made to all Settlement Class Members who timely submit a valid proof of claim form, if the Court approves the Settlement and after all proof of claim forms have been reviewed and processed, and any appeals are resolved. Please be patient.
- All capitalized terms not otherwise defined herein shall have the same meanings as set forth in the Stipulation.

SUMMARY NOTICE

Statement of Plaintiff Recovery

Lead Plaintiffs Michael A. Lowery and Ramesh A. Patel, on behalf of themselves and the Settlement Class (collectively, “Lead Plaintiffs”) have entered into a proposed Settlement with all Defendants that, if approved by the Court, will resolve this Action in its entirety.

A settlement fund of \$2,868,000.00 in cash, plus interest (“Gross Settlement Fund”), is being established for the benefit of the Settlement Class described herein.

Lead Plaintiffs estimate that the average recovery per damaged share of AMRI common stock under the Settlement is \$0.7116 per share for the approximately 4.03 million shares of AMRI common stock damaged during the Class Period. A share may have been traded more than once during the Class Period. This estimate solely reflects the average recovery per damaged share of AMRI common stock. The indicated average recovery per share will be the total average recovery for all purchases of that share. This is not an estimate of the actual recovery per share you should expect. Your actual recovery will depend on the aggregate losses of all Settlement Class Members, the date(s) you purchased and sold AMRI stock and the total number and amount of claims filed. If not all Settlement Class Members submit claims, your actual recovery could be more than the estimated average amount.

Lead Counsel will make an application to the Court for an award of attorneys’ fees and reimbursement of out-of-pocket costs and expenses incurred in prosecuting the Settlement Class’ claims, including the fees of Lead Plaintiffs’ experts and consultants, from the Gross Settlement Fund in connection with this Settlement. It is expected that the application will seek a sum no greater than \$956,000.00, which constitutes approximately 33 1/3% of the Gross Settlement Fund.

The attorneys representing Lead Plaintiffs and the Settlement Class have expended considerable time and effort in prosecuting this litigation on a contingent-fee basis, and have advanced all of the expenses of the litigation, with the expectation that if they were successful in obtaining a recovery for the Settlement Class, they would be paid from such recovery. In this type of litigation, it is customary for the plaintiff’s counsel to be awarded a percentage of the common fund recovery as their attorneys’ fees.

In addition, Lead Plaintiffs will apply for an Award to Lead Plaintiffs of no more than \$12,000.00 (\$6,000 each) for reimbursement for their reasonable costs and expenses (including lost wages) directly related to their representation of the Settlement Class.

If approved by the Court, these amounts will be paid from the Gross Settlement Fund. If the above amounts are requested and approved by the Court, the average cost per share of damaged common stock will be approximately \$0.2402 per share, making the estimated recovery per damaged share after deduction of the requested attorneys’ fees and expenses and Award to Lead Plaintiffs, \$0.4714 per share.

The average recovery also assumes that all Settlement Class Members receive and cash their distribution checks. If not all Settlement Class Members cash their distribution checks and a second distribution becomes necessary, your actual recovery could be more than the estimated average amount. Additionally, a Settlement Class Member’s actual recovery will be determined by the Plan of Allocation of the Net Settlement Fund described below, and will depend upon, among other things, when during the Settlement Class Period a Settlement Class Member purchased AMRI stock, and when and if such stock was sold. Under one or more of these factors, individual Settlement Class Members could receive more or less than the estimated average per-share amount.

Statement of Potential Outcome of Case

The Parties disagree about both liability and damages and do not agree on the average amount of damages per share, if any, that would be recoverable if Lead Plaintiffs were to have prevailed on each claim alleged. Among the many key issues about which Lead Plaintiffs and Defendants disagree are: (i) whether Defendants violated the securities laws or otherwise engaged in any wrongdoing; (ii) the extent (if any) that the alleged misrepresentations and omissions influenced the trading prices of AMRI common stock during the Settlement Class Period; and (iii) the method for determining whether, and the extent to which (if any), purchasers of AMRI stock suffered injury and damages that could be recovered at trial.

Defendants deny that they are liable to the Lead Plaintiffs or the Settlement Class and deny that Lead Plaintiffs or the Settlement Class have suffered any recoverable damages whatsoever.

Inquiries

Please do not contact the Court regarding this Notice. All inquiries concerning this Notice, the Proof of Claim and Release form, or any other questions by Settlement Class Members should be directed to:

Albany Molecular Research, Inc. Litigation c/o Strategic Claims Services P.O. Box 230 600 N. Jackson Street, Ste. 3 Media, Pennsylvania 19063 Tel: 866-274-4004 Fax: 610-565-7985 info@strategicclaims.net	OR	Phillip Kim, Esq. Laurence Rosen, Esq. THE ROSEN LAW FIRM, P.A. 275 Madison Avenue, 34 th Floor New York, NY 10016 Tel: 212-686-1060 Fax: 212-202-3827 info@rosenlegal.com
---	----	--

Reasons for the Settlement

Lead Plaintiffs, along with Lead Counsel, who has extensive experience in class action litigation, agreed to the Settlement after considering, among other things: (a) the substantial cash benefits to Settlement Class Members of the Settlement; (b) the desirability of consummating the Stipulation in order to provide certain and effective relief to Settlement Class Members at this juncture of the Action and without further delay; (c) the uncertainty of being able to adequately state a claim and ultimately prove the allegations in the Action; (d) Defendants’ likely positions, expressed during the pendency of the litigation and also in connection with settlement negotiations, concerning the various liability, causation, and damages issues; (e) the attendant risks of litigation, especially in complex actions such as this, as well as the difficulties and delays inherent in such litigation (including any appeals); and (f) Lead Plaintiffs’ and Lead Counsel’s belief that the Settlement is fair, reasonable, and adequate and in the best interests of all Settlement Class Members.

For Defendants, who deny all allegations of wrongdoing or liability whatsoever, the principal reasons for entering into the Settlement are to bring to an end the substantial expenses, burdens, risks, and uncertainties associated with continued litigation of this Action; to finally put to rest those claims and the underlying matters; and to avoid further expense and disruption to the management and operation of the corporate Defendant’s business due to the prosecution and defense of this Action.

WHAT THIS NOTICE CONTAINS

TABLE OF CONTENTS

	Page
BASIC INFORMATION.....	5
1. Why did I get this notice package?.....	5
2. What is this lawsuit about?.....	5
3. Why is this a class action?.....	5
4. Why is there a settlement?.....	5
WHO IS IN THE SETTLEMENT.....	6
5. How do I know if I am part of the Settlement?.....	6
6. Are there exceptions to being included?.....	6
7. What if I am still not sure if I am included?.....	6
THE SETTLEMENT BENEFITS — WHAT DOES THE SETTLEMENT PROVIDE?.....	6
8. What is the Settlement Fund?.....	6
9. How much will my payment be?.....	7
HOW YOU GET A PAYMENT — SUBMITTING A PROOF OF CLAIM AND RELEASE...10	
10. How can I get a payment?.....	10
11. When will I get my payment?.....	10
12. What am I giving up to get a payment or stay in the Settlement Class?.....	10
EXCLUDING YOURSELF FROM THE SETTLEMENT.....	11
13. How do I exclude myself from the proposed Settlement?.....	11
14. If I do not exclude myself, can I sue the Defendants and the other Released Persons for the same thing later?.....	11
15. If I exclude myself, can I get money from the proposed Settlement?.....	11
THE LAWYERS REPRESENTING YOU.....	11
16. Do I have a lawyer in this case?.....	11
17. How will the lawyers be paid?.....	11
OBJECTING TO THE SETTLEMENT.....	12
18. How do I tell the Court that I do not like the proposed Settlement?.....	12
19. What is the difference between objecting and excluding?.....	12
THE FINAL FAIRNESS HEARING.....	12
20. When and where will the Court decide whether to approve the proposed Settlement?.....	13
21. Do I have to come to the hearing?.....	13
22. May I speak at the hearing?.....	13
IF YOU DO NOTHING.....	13
23. What happens if I do nothing at all?.....	13
GETTING MORE INFORMATION.....	14
24. Are there more details about the proposed Settlement?.....	14
25. How do I get more information?.....	14

BASIC INFORMATION

1. Why did I get this notice package?

The Court authorized this Notice to be sent to you because records show that between August 5, 2014 to November 5, 2014, inclusive, you may have purchased AMRI common stock.

If this description applies to you, you have a right to know about the proposed Settlement of this class action lawsuit, and about all of your options, before the Court decides whether to approve the Settlement. If the Court approves the Settlement, and after any objections and appeals are resolved, an administrator appointed by the Court will make the payments that the Settlement allows.

This Notice explains the lawsuit, the Settlement, Settlement Class Members' legal rights, what benefits are available, who is eligible for them, and how to get them.

The Court in charge of this Action is the United States District Court for the Eastern District of New York, in Brooklyn, NY, and the case is known as *Gauquie v. Albany Molecular Research, Inc. et al*, Case No. 1:14-cv-06637-FB-SMG (E.D.N.Y.). The Action is assigned to and overseen by the Honorable Frederic Block, United States District Judge.

The individuals that are suing, namely Michael A. Lowery and Ramesh A. Patel (collectively "Lead Plaintiffs") are called "Plaintiffs." The company and persons being sued, namely AMRI, William Marth and Michael Nolan, are called the Defendants.

2. What is this lawsuit about?

Plaintiffs claim that Defendants violated federal securities laws by misrepresenting and/or omitting information regarding a power outage that occurred in late July 2014 at an AMRI manufacturing facility. The Complaint asserts unspecified damages and asserts claims against Defendants under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder. Defendants vigorously deny the allegations of wrongdoing and any liability whatsoever. The Court has made no decision regarding the merits of the claims.

3. Why is this a class action?

In a class action, one or more persons or entities sue on behalf of people who have similar claims. All these people are referred to as a class, and each is a class member. Bringing a case, such as this one, as a class action allows the adjudication of many similar claims of persons and entities that might be economically too small to bring as individual actions. One court resolves the issues for all Settlement Class Members at the same time, except for those who exclude themselves from the Settlement Class.

4. Why is there a settlement?

On November 12, 2014, purported stockholders of AMRI brought a putative class action lawsuit in the United States District Court for the Eastern District of New York, titled *Gauquie v. Albany Molecular Research, Inc. et al*, Case No. 1:14-cv-06637-FB-SMG. On January 26, 2015, the Court appointed Ramesh A. Patel and Michael W. Lowery as lead plaintiffs, and appointed The Rosen Law Firm, P.A. as lead counsel.

Lead Plaintiffs filed an Amended Class Action Complaint on March 31, 2015 (the "Complaint") on behalf of purchasers of AMRI common stock during the Settlement Class Period, which named AMRI, William Marth and Michael Nolan as defendants. The Complaint alleges that Defendants violated federal securities laws by misrepresenting and/or omitting information regarding a power outage that occurred in late July 2014 at an AMRI manufacturing facility. The complaint seeks an unspecified amount of damages and asserts claims against Defendants under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder.

On November 20, 2015, the parties submitted their briefing on Defendants' motion to dismiss the complaint to the Court. On July 26, 2016, the Court issued an order denying Defendants' motion to dismiss. On September 6, 2016, the parties submitted their briefing on Defendants' motion for reconsideration of the Court's order denying their motion to dismiss. This motion is pending.

On September 23, 2016, the parties filed a joint case management statement pursuant to which Defendants could take discovery regarding Lead Plaintiffs' suitability to serve as class representatives until November 1, 2016, and could then submit an application to bifurcate class and merits discovery. Otherwise, class and merits discovery would proceed simultaneously beginning on November 4, 2016. The Court granted two extensions of the November 1, 2016 deadline to enable the scheduling of Lead Plaintiffs' depositions, and one extension to reserve resources in light of the Parties' scheduled mediation. During September through November 2016, Defendants served and Lead Plaintiffs responded to document requests and interrogatories. In addition, Defendants took the depositions of both Lead Plaintiffs.

On December 12, 2016, the parties participated in an all-day mediation session before the Honorable Faith S. Hochberg of Hochberg ADR. Prior to the mediation, the Parties exchanged mediation statements. Lead Plaintiffs and Defendants reached an agreement-in-principle to settle this matter during the December 12, 2016 mediation, and subsequently negotiated the terms of the Stipulation, which was filed with the Court on June 23, 2017.

Thus, the Court did not finally decide in favor of Plaintiffs or Defendants. Instead, both sides formally agreed to a settlement. By settling, the parties avoid the risks, uncertainty and additional costs of a trial, and the affected Settlement Class Members may receive compensation. Plaintiffs and Lead Counsel believe the Settlement is best for all Settlement Class Members.

WHO IS IN THE SETTLEMENT

To see if you may get money from this Settlement, you first have to determine whether you are a Settlement Class Member.

5. How do I know if I am part of the Settlement?

The Court decided that everyone who fits this description is a Settlement Class Member:

All Persons who purchased AMRI common stock during the period from and including August 5, 2014 through November 5, 2014.

If you are part of the Settlement Class, you are a Settlement Class Member and part of the Settlement unless one of the exceptions described in the answer to question 6 below apply to you.

6. Are there exceptions to being included?

Yes. You are not a Settlement Class Member if you are a Defendant in the Action, a member of the immediate family of any Individual Defendant, a present or former officer or director of AMRI, or the legal representative, heir, successor or assign of any of the foregoing, or you are an entity in which Defendants have or had a controlling interest.

Additionally, anyone who submits a valid and timely request for exclusion from the Settlement Class, in accordance with the procedures set forth in question 13, is not considered a Settlement Class Member and cannot participate in the Settlement.

7. What if I am still not sure if I am included?

If you are still not sure whether you are included in the Settlement, you can ask for free help. You can call the Claims Administrator, Strategic Claims Services, toll-free at 866-274-4004, send an e-mail to info@strategicclaims.net, or write to: Albany Molecular Research, Inc. Litigation, c/o Strategic Claims Services, P.O. Box 230, 600 N. Jackson Street, Ste. 3, Media, Pennsylvania 19063.

THE SETTLEMENT BENEFITS — WHAT DOES THE SETTLEMENT PROVIDE?

8. What is the Settlement Fund?

In exchange for the Settlement and dismissal of the action, Defendants have agreed to create a Two Million Eight Hundred Sixty Eight Thousand Dollars (\$2,868,000.00) settlement fund to be distributed, after various Court-approved fees and expenses, among all Settlement Class Members who submit valid claims.

9. How much will my payment be?

You can calculate your recovery in accordance with the formulas shown below in the Plan of Allocation of the Net Settlement Fund. Your share of the Net Settlement Fund will or may depend on: (i) the number of claims filed; (ii) the dates you purchased and sold AMRI common stock; (iii) the prices of your purchases and sales; (iv) the amount of administrative costs, including the costs of notice; (v) the amount awarded by the Court to Lead Counsel for attorneys' fees, costs, and expenses; and (vi) the awards to Lead Plaintiffs.

The Claims Administrator will determine each Authorized Claimant's *pro rata* share of the Net Settlement Fund based upon each Authorized Claimant's valid "Recognized Claim." The Recognized Claim (also referred to as "Recognized Loss") formula is not intended to be an estimate of the amount that a Settlement Class Member might have been able to recover after a trial; it also is not an estimate of the amount that will be paid to Authorized Claimants pursuant to the Settlement. The Recognized Claim formula is the basis upon which the Net Settlement Fund will be proportionately allocated to the Settlement Class Members with valid claims.

The Net Settlement Fund will be distributed to Settlement Class Members who submit valid, timely claim forms ("Authorized Claimants") under the below Plan of Allocation, which reflects Plaintiffs' contention that because of the alleged misrepresentations and omissions made by Defendants, the price of AMRI common stock was artificially inflated during the Settlement Class Period and that disclosures and materialization of the true facts caused changes in the inflated stock price.

The Recognized Claim, or compensable loss per share, of each Authorized Claimant shall be calculated according to the proposed Plan of Allocation of the Net Settlement Fund set forth below.

PROPOSED PLAN OF ALLOCATION OF THE NET SETTLEMENT FUND

The Plan of Allocation is a matter separate and apart from the proposed Settlement, and any decision by the Court concerning the Plan of Allocation shall not affect the validity or finality of the proposed Settlement. The Court may approve the Plan of Allocation with or without modifications agreed to among the parties, or another plan of allocation, without further notice to Settlement Class Members. Any orders regarding a modification of the Plan of Allocation will be posted to the Claims Administrator's website, www.strategicclaims.net.

The Claims Administrator shall determine each Authorized Claimant's *pro rata* share of the Net Settlement Fund based upon each Authorized Claimant's Recognized Loss. Please Note: The Recognized Loss formula, set forth below, is not intended to be an estimate of the amount of what a Settlement Class Member might have been able to recover after a trial, nor is it an estimate of the amount that will be paid to Authorized Claimants pursuant to the Settlement. The Recognized Loss formula is the basis upon which the Net Settlement Fund will be proportionately allocated to the Authorized Claimants. To the extent there are sufficient funds remaining in the Net Settlement Fund, each Authorized Claimant will receive an amount equal to the Authorized Claimant's Recognized Loss. If, however, the Net Settlement Fund is not sufficient to permit payment of the total Recognized Loss of each Authorized Claimant, then each Authorized Claimant shall be paid the percentage of the Net Settlement Fund that each Authorized Claimant's Recognized Loss bears to the total Recognized Losses of all Authorized Claimants (*i.e.*, "pro rata share"). Payment in this manner shall be deemed conclusive against all Authorized Claimants. No distribution will be made on a claim where the potential distribution amount is less than ten dollars (\$10.00) in cash.

If any of the Net Settlement Fund remains by reason of uncashed checks, or otherwise, after the Claims Administrator has made reasonable and diligent efforts to have Authorized Claimants who are entitled to participate in the distribution of the Net Settlement Fund cash their distribution checks, then any balance remaining in the Net Settlement Fund six (6) months after the initial distribution of such funds shall be used: (i) first, to pay any amounts mistakenly omitted from the initial distribution to Authorized Claimants or to pay any late, but otherwise valid and fully documented claims received after the cut-off date used to make the initial distribution, provided that such distributions to any late post-distribution claimants meet all of the other criteria for inclusion in the initial distribution, including the \$10.00 minimum check amount set forth in the Notice; (ii) second, to pay any additional Administrative Costs incurred in administering the Settlement; and (iii) finally, to make a second distribution to

Authorized Claimants who cashed their checks from the initial distribution and who would receive at least \$10.00 from such second distribution, after payment of the estimated costs or fees to be incurred in administering the Net Settlement Fund and in making this second distribution, if such second distribution is economically feasible. If six (6) months after such second distribution, if undertaken, or if such second distribution is not undertaken, and if any funds shall remain in the Net Settlement Fund after the Claims Administrator has made reasonable and diligent efforts to have Authorized Claimants who are entitled to participate in this Settlement cash their checks, then any funds remaining in the Net Settlement Fund shall be donated to a non-profit 501(c)(3) organization(s) selected by Lead Counsel.

THE BASIS FOR CALCULATING YOUR RECOGNIZED CLAIM:

Each Authorized Claimant shall be allocated a pro rata share of the Net Settlement Fund based on his, her or its Recognized Loss as compared to the total Recognized Losses of all Authorized Claimants.

A) Recognized Loss Calculation of Common Stock Purchased During the Class Period:

1) For shares of common stock purchased between August 5, 2014 and November 4, 2014, inclusive:

- a. For shares retained at the end of trading on February 3, 2015, the Recognized Loss shall be the lesser of:
 - (1) \$5.90 per share¹; or
 - (2) the difference between the purchase price per share and \$16.06 per share.²
- b. For shares sold between August 5, 2014 and November 4, 2014, inclusive, the Recognized Loss shall be zero.
- c. For shares sold on November 5, 2014, the Recognized Loss shall be the lesser of:
 - (1) \$5.90 per share; or
 - (2) the difference between the purchase price per share and sale price per share.
- d. For shares sold between November 6, 2014 and February 3, 2015, inclusive, the Recognized Loss shall be the lesser of:
 - (1) \$5.90 per share; or
 - (2) the difference between the purchase price per share and the average closing stock price as of date of sale provided in Table A below.

2) For shares of common stock purchased on November 5, 2014, the Recognized Loss shall be zero.

To the extent a claimant had a trading gain or “broke even” from his, her or its overall transactions in AMRI shares during the Settlement Class Period, the value of the Recognized Claim will be zero and the claimant will not be entitled to a share of the Net Settlement Fund. To the extent that a claimant suffered a trading loss on his, her or its overall transactions in AMRI shares during the Settlement Class Period, but that trading loss was less than the Recognized Claim calculated above, then the Recognized Claim shall be limited to the amount of the claimant’s actual trading loss.

For purposes of calculating your Recognized Claim, the date of purchase or sale is the “contract” or “trade” date and not the “settlement” or “payment” date. The receipt or grant by gift, inheritance or

¹ \$5.90/share is excess price decline, or artificial inflation due to the alleged fraud, determined by a financial expert hired by Lead Counsel.

² Pursuant to Section 21(D)(e)(1) of the Private Securities Litigation Reform Act of 1995, “in any private action arising under this title in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90 day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated.” \$16.06 per share was the mean (average) daily closing trading price of AMRI’s common stock during the 90 day period beginning on November 6, 2014 and ending on February 3, 2015.

operation of law of AMRI shares shall not be deemed a purchase or sale of AMRI shares for the calculation of an Authorized Claimant's Recognized Claim. The covering purchase of a short sale is not an eligible purchase for purposes of calculating Recognized Claims.

For purposes of calculating your Recognized Claim, all purchases and sales shall be matched on a First In First Out ("FIFO") basis in chronological order. Therefore, on the Proof of Claim and Release form enclosed with this Notice, you must provide all of your purchases and sales of AMRI shares during the time period from August 5, 2014 through February 3, 2015, inclusive.

Payment pursuant to the Plan of Allocation approved by the Court shall be conclusive against all Authorized Claimants. No person shall have any claim against Defendants, Defendants' Counsel, Lead Plaintiffs, Lead Counsel or the Claims Administrator or other agent designated by Lead Counsel based on the distributions made substantially in accordance with the Stipulation and the Settlement contained therein, the Plan of Allocation, or further orders of the Court. Each claimant shall be deemed to have submitted to the jurisdiction of the Court with respect to the claimant's Proof of Claim and Release form. All persons involved in the review, verification, calculation, tabulation, or any other aspect of the processing of the claims submitted in connection with the Settlement, or otherwise involved in the administration or taxation of the Gross Settlement Fund or the Net Settlement Fund shall be released and discharged from any and all claims arising out of such involvement, and all Settlement Class Members, whether or not they are to receive payment from the Net Settlement Fund, will be barred from making any further claim against the Net Settlement Fund beyond the amount allocated to them as provided in any distribution orders entered by the Court.

B) Are there any further limitations on the amount I may receive?

- 1) Transactions during the Class Period resulting in a gain shall be netted against the Class Member's transactions resulting in a loss to arrive at the Recognized Loss.
- 2) Any Class members whose collective transactions in AMRI common stock during the Class Period resulted in a net gain shall not be entitled to share in the Net Settlement Fund.
- 3) The purchase and sales prices exclude any brokerage commissions, transfer taxes or other fees.
- 4) The covering purchase of a short sale is not an eligible purchase. Gifts and transfers are not eligible purchases.

TABLE A					
Date	<u>Closing Price</u>	<u>Average Closing Price</u>	Date	<u>Closing Price</u>	<u>Average Closing Price</u>
11/6/2014	\$16.09	\$16.09	12/19/2014	\$14.89	\$15.96
11/7/2014	\$16.84	\$16.47	12/22/2014	\$15.42	\$15.95
11/10/2014	\$17.10	\$16.68	12/23/2014	\$15.14	\$15.92
11/11/2014	\$17.55	\$16.89	12/24/2014	\$15.19	\$15.90
11/12/2014	\$16.83	\$16.88	12/26/2014	\$15.63	\$15.89
11/13/2014	\$16.71	\$16.85	12/29/2014	\$15.70	\$15.89
11/14/2014	\$16.13	\$16.75	12/30/2014	\$15.87	\$15.89
11/17/2014	\$15.90	\$16.64	12/31/2014	\$16.28	\$15.90
11/18/2014	\$16.24	\$16.60	1/2/2015	\$15.69	\$15.89
11/19/2014	\$16.24	\$16.56	1/5/2015	\$15.07	\$15.87
11/20/2014	\$16.35	\$16.54	1/6/2015	\$15.28	\$15.86
11/21/2014	\$15.69	\$16.47	1/7/2015	\$16.00	\$15.86
11/24/2014	\$15.79	\$16.42	1/8/2015	\$15.70	\$15.86
11/25/2014	\$15.50	\$16.35	1/9/2015	\$16.35	\$15.87
11/26/2014	\$15.85	\$16.32	1/12/2015	\$16.63	\$15.89
11/28/2014	\$16.27	\$16.32	1/13/2015	\$17.16	\$15.91

12/1/2014	\$15.46	\$16.27	1/14/2015	\$17.26	\$15.94
12/2/2014	\$15.86	\$16.24	1/15/2015	\$17.10	\$15.97
12/3/2014	\$15.87	\$16.22	1/16/2015	\$17.00	\$15.99
12/4/2014	\$15.77	\$16.20	1/20/2015	\$16.67	\$16.00
12/5/2014	\$16.21	\$16.20	1/21/2015	\$16.48	\$16.01
12/8/2014	\$16.18	\$16.20	1/22/2015	\$16.29	\$16.02
12/9/2014	\$16.67	\$16.22	1/23/2015	\$16.09	\$16.02
12/10/2014	\$16.11	\$16.22	1/26/2015	\$16.49	\$16.03
12/11/2014	\$15.98	\$16.21	1/27/2015	\$16.22	\$16.03
12/12/2014	\$15.84	\$16.19	1/28/2015	\$16.24	\$16.03
12/15/2014	\$14.94	\$16.15	1/29/2015	\$16.80	\$16.05
12/16/2014	\$14.19	\$16.08	1/30/2015	\$16.33	\$16.05
12/17/2014	\$14.79	\$16.03	2/2/2015	\$16.34	\$16.06
12/18/2014	\$15.04	\$16.00	2/3/2015	\$16.37	\$16.06

HOW YOU GET A PAYMENT — SUBMITTING A PROOF OF CLAIM AND RELEASE

10. How can I get a payment?

If you qualify as a Settlement Class Member, to be eligible for a settlement payment from the proceeds of the Settlement approved by the Court, you must send in the Proof of Claim and Release form enclosed with this Notice. You also may get a Proof of Claim and Release form on the internet at www.strategicclaims.net or by calling the Claims Administrator at 866-274-4004. Read the instructions carefully, fill out the form, include all the documents requested, sign the form, and send it by first-class mail, postmarked no later than September 21, 2017 to the Claims Administrator:

Albany Molecular Research, Inc. Litigation
c/o Strategic Claims Services
P.O. Box 230
600 N. Jackson Street, Ste. 3
Media, Pennsylvania 19063
info@strategicclaims.net
Fax: (610) 565-7985

11. When will I get my payment?

The Court will hold a hearing on October 12, 2017 at 12:00 p.m. to decide whether to approve the Settlement. If the Court approves the Settlement after that, there may be appeals. It is always uncertain how these appeals will be resolved, and resolving them can take a long time, perhaps more than a year. It also takes a long time, often many months, for all claims to be accurately reviewed and processed. Please be patient.

12. What am I giving up to get a payment or stay in the Settlement Class?

Unless you exclude yourself from the Settlement Class by the September 21, 2017 deadline, you will be a member of the Settlement Class and will be bound by the release of claims if the Settlement is approved. That means you and all other Settlement Class Members, and each of your respective personal representatives, immediate family, trustees, heirs, executors, administrators, parent entities, associates, affiliates, predecessors, successors and assigns, and any other person or entity claiming to be acting on behalf of any of you, will release (agreeing never to sue, continue to sue, or be part of any other lawsuit) any claims which arise out of, are based upon or relate in any way to the purchase or sale of AMRI common stock during the Settlement Class Period. It means that all of the Court's orders in the Action will apply to you and legally bind you. The specific terms of the release and related terms are included in the Stipulation.

If you remain a member of the Settlement Class, all of the Court's orders will apply to you and legally bind you.

EXCLUDING YOURSELF FROM THE SETTLEMENT

If you do not want a payment from this Settlement, but you want to keep any right you may have to sue or continue to sue Defendants and the other Released Persons, on your own, concerning the Released Claims, then you must take steps to exclude yourself. This is called excluding yourself or "opting out" of the Settlement Class.

13. How do I exclude myself from the proposed Settlement?

To exclude yourself from the Settlement Class, you must mail a letter stating that you "request exclusion from the Settlement Class in Gauquie v. Albany Molecular Research, Inc." You cannot exclude yourself by telephone or e-mail. Your letter must include your name, mailing address, daytime telephone number, e-mail address, and your signature. Your letter must also indicate the number of shares of AMRI common stock owned as of November 5, 2014 and the date(s), price(s) and number(s) of shares of AMRI common stock purchased and sold during the Settlement Class Period. No request for exclusion will be considered valid unless all of the information described above is included in any such request. You must mail your exclusion request by first-class mail, postmarked no later than September 21, 2017 to:

Albany Molecular Research, Inc. Litigation
c/o Strategic Claims Services
P.O. Box 230
600 N. Jackson Street, Ste. 3
Media, Pennsylvania 19063

If you ask to be excluded, you will not get any Settlement payment, and you cannot object to the Settlement. You will not be legally bound by anything that happens in this lawsuit, and you may be able to sue (or continue to sue) the Defendants and the other Released Persons in the future.

14. If I do not exclude myself, can I sue the Defendants and the other Released Persons for the same thing later?

No. Unless you properly exclude yourself, you give up any rights to sue Defendants and the other Released Persons for any and all Released Claims. If you do not exclude yourself, you will not be entitled to receive any recovery in any other action against any of the Released Persons based on or arising out of the Released Claims.

15. If I exclude myself, can I get money from the proposed Settlement?

No. If you exclude yourself, you will not receive any money from this Settlement. But, you may exercise any right you may have to sue, continue to sue, or be part of a different lawsuit against Defendants and the other Released Persons.

THE LAWYERS REPRESENTING YOU

16. Do I have a lawyer in this case?

The Court ordered that The Rosen Law Firm, P.A. will represent Plaintiffs and all Settlement Class Members. These lawyers are called Lead Counsel.

You will not be separately charged for these lawyers. The Court will determine the amount of Lead Counsel's fees and expenses, which will be paid from the Gross Settlement Fund. If you want to be represented by your own lawyer, you may hire one at your own expense.

17. How will the lawyers be paid?

Lead Counsel will ask the Court to award attorneys' fees and expenses from the Gross Settlement Fund of approximately \$956,000, or approximately 33 1/3% of the Gross Settlement Fund, which will include the reimbursement of expenses incurred by in connection with the prosecution of this Action.

After the Final Fairness Hearing, Lead Counsel, without further notice to the Settlement Class, may apply to the Court for additional expenses incurred in connection with administering and distributing the settlement proceeds to the members of the Settlement Class.

The motion for attorneys’ fees and expenses will be submitted on behalf of The Rosen Law Firm, P.A.

OBJECTING TO THE SETTLEMENT

You can tell the Court that you do not agree with the Settlement or some part of it.

18. How do I tell the Court that I do not like the proposed Settlement?

If you are a Settlement Class Member, you can object to the Settlement or any of its terms, the proposed Plan of Allocation of the Net Settlement Fund, and/or the application by Lead Counsel for an award of attorneys’ fees and expenses. You may write to the Court setting out your objection. You may give reasons why you think the Court should not approve any or all of the Settlement terms. If you would like the Court to consider your views, you must file a proper objection within the deadline identified, and according to the following procedures.

To object, you must send a signed letter stating that you object to the proposed Settlement, Plan of Allocation or application for an award of attorneys’ fees and expenses in *Gauquie v. Albany Molecular Research, Inc. et al*, Case No. 1:14-cv-06637-FB-SMG (E.D.N.Y.). Be sure to include your name, address, daytime telephone number, e-mail address, and your signature, identify and supply documentation showing your purchases and sales of AMRI common stock during the Settlement Class Period, and state the reasons why you object to the Settlement, including all legal support you wish to bring to the Court’s attention and any evidence you have to support your objection. Your objection must be filed with the Court and mailed or delivered to the following counsel at all of the following addresses, so that it is received no later than September 21, 2017:

<p>The Court: Clerk of the Court United States District Court for The Eastern District of New York 225 Cadman Plaza East Brooklyn, New York 11201</p>	<p>Lead Counsel: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, New York 10016</p>	<p>Counsel for Defendants: Deborah S. Birnbach, Esq. Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210</p>
--	---	--

You do not need to go to the Final Fairness Hearing to have your written objection considered by the Court. Any Settlement Class Member who has not previously submitted a request for exclusion from the Settlement Class and who has complied with the objection procedures set out in this question 18 may also appear at the Final Fairness Hearing and be heard, to the extent allowed by the Court, to state his, her or its objection to the Settlement, the Plan of Allocation, or Lead Counsel’s motion for an award of attorneys’ fees and reimbursement of expenses. Any such objector may appear in person or arrange, at his or her own expense, for a lawyer to represent him or her at the Final Fairness Hearing.

19. What is the difference between objecting and excluding?

Objecting is telling the Court that you do not like something about the proposed Settlement. You can object only if you stay in the Settlement Class and follow the objection procedures described above. Excluding yourself is telling the Court that you do not want to be part of the Settlement Class. If you exclude yourself, you have no basis to object because the case no longer affects you.

THE FINAL FAIRNESS HEARING

The Court will hold a hearing, called a Final Fairness Hearing, to consider whether to approve the proposed Settlement. At or after the Final Fairness Hearing, the Court will also decide whether to approve the Plan of Allocation of the Net Settlement Fund and Lead Counsel’s application for attorneys’ fees and expenses and any award to Plaintiffs.

20. When and where will the Court decide whether to approve the proposed Settlement?

The Court will hold the Final Fairness Hearing on October 12, 2017 at 12:00 p.m. in Courtroom 1040 at the United States District Court for the Eastern District of New York, United States Courthouse, 225 Cadman Plaza East, Brooklyn, NY 11201.

At this hearing, the Court will consider whether the Settlement is fair, reasonable and adequate and should be approved, and will also consider the proposed Plan of Allocation and the application of Lead Counsel for attorneys' fees and reimbursement of expenses. The Court will take into consideration any written objections filed in accordance with the instructions in question 18. The Court may also decide how much to pay Plaintiffs' lawyers for their fees and expenses. At or after the hearing, the Court will decide whether to approve the Settlement. We do not know how long these decisions will take.

Also at the hearing the Court will decide whether to approve the dismissal with prejudice of all claims against Defendants.

21. Do I have to come to the hearing?

No. Lead Counsel will answer any questions the Court may have. But, you are welcome to attend at your own expense. If you send an objection, you do not have to come to Court to discuss it. As long as you filed your written objection on time, the Court will consider it. You may also pay your own lawyer to attend, but it is not required. If you do hire your own lawyer, he or she must file and serve a Notice of Appearance in the manner described in the answer to question 22 below.

Please be aware that the Court may change the date or time of the Final Fairness Hearing without further notice to Settlement Class Members. If you or your attorney plan to come to the hearing, you should check with Lead Counsel before coming to be sure that the date or time has not changed.

Settlement Class Members do not need to appear at the hearing or take any other action to indicate their approval of the matters being considered at the hearing.

22. May I speak at the hearing?

You may speak at the Final Fairness Hearing if you are a Settlement Class Member and you filed an objection to the Settlement, the Plan of Allocation, and/or Lead Counsel's application for an award of attorneys' fees and expenses in the manner and the time period described in the answer to question 18 above. If you plan to have an attorney speak on your behalf at the Final Fairness Hearing, your attorney must, on or before September 21, 2017, file a Notice of Appearance in this Action with the Clerk of the Court and deliver a copy to Lead Counsel and Counsel for Defendants at the addresses listed in the answer to question 18 above.

If you or your attorney plan to attend the Final Fairness Hearing and present evidence at the hearing, your written objection (prepared and submitted in accordance with the answer to question 18 above) and must identify any witness you or your attorney may seek to call to testify, and must identify any documents or other exhibits you or your attorney may seek to introduce into evidence.

IF YOU DO NOTHING

23. What happens if I do nothing at all?

If you do nothing, you will get no money from this Settlement and you will be precluded from starting a lawsuit, continuing with a lawsuit, or being part of any other lawsuit against the Defendants and the other Released Persons concerning the Released Claims, ever again. To share in the Net Settlement Fund, you must submit a Proof of Claim and Release form (see question 10). To start, continue or be a part of any other lawsuit against the Defendants and the other Released Persons concerning the Released Claims in this case, you must exclude yourself from the Settlement Class (see question 13).

GETTING MORE INFORMATION

24. Are there more details about the proposed Settlement?

This Notice summarizes the proposed Settlement. More details are in the Stipulation of Settlement dated June 23, 2017. You can get a copy of the Stipulation by contacting Laurence Rosen, Esq. or Phillip Kim, Esq., The Rosen Law Firm P.A., 275 Madison Avenue, 34th Floor, New York, New York 10016.

You also can call the Claims Administrator toll-free at 866-274-4004; send an e-mail to info@strategicclaims.net; write to Albany Molecular Research, Inc. Litigation, c/o Strategic Claims Services, P.O. Box 230, 600 N. Jackson St. Ste 3, Media, PA 19063; or visit the website at www.strategicclaims.net, where you will find answers to common questions about the Settlement, a Proof of Claim and Release form, and other information to help you determine whether you are a Settlement Class Member and whether you are eligible for a payment.

25. How do I get more information?

For even more detailed information concerning the matters involved in this action, reference is made to the pleadings, to the Stipulation, to the Orders entered by the Court and the other papers filed in the Action, most of which may be inspected at the Office of the Clerk of the United States District Court for the Eastern District of New York, 225 Cadman Plaza East, Brooklyn, NY 11201, on weekdays (other than court holidays) between 9:00 a.m. and 4:00 p.m. Subscribers to PACER, a fee-based service, can also view the papers filed publicly in the action through the Court's on-line Case Management/Electronic Case Files System at <https://ecf.cacd.uscourts.gov>.

***PLEASE DIRECT YOUR QUESTIONS TO THE CLAIMS ADMINISTRATOR
OR TO LEAD COUNSEL. DO NOT CONTACT THE COURT.***

SPECIAL NOTICE TO SECURITIES BROKERS AND OTHER NOMINEES

If, between August 5, 2014 and November 5, 2014 inclusive, you purchased the common stock of Albany Molecular Research, Inc. for the beneficial interest of a person or organization other than yourself, the Court has directed that, **WITHIN TEN (10) DAYS OF YOUR RECEIPT OF THIS NOTICE**, you either (a) provide to the Claims Administrator the name and last known address of each person or organization for whom or which you purchased such AMRI common stock during such time period or (b) request additional copies of this Notice and the Proof of Claim and Release form, which will be provided to you free of charge, and within ten (10) days mail the Notice and Proof of Claim and Release form directly to the beneficial owners of the AMRI common stock. If you choose to follow alternative procedure (b), the Court has directed that, upon such mailing, you send a statement to the Claims Administrator confirming that the mailing was made as directed. You are entitled to reimbursement from the Settlement Fund of your reasonable out-of-pocket expenses actually incurred in connection with the foregoing. Those expenses will be paid upon request and submission of appropriate supporting documentation. If you follow alternative procedure (b), your reimbursement of reasonable out-of-pocket postage and expenses are not to exceed \$.75 per unit. All communications regarding the foregoing should be addressed to the Claims Administrator at the address listed in question 24 above.

Dated: Brooklyn, New York
June 23, 2017

BY ORDER OF THE UNITED STATES
DISTRICT COURT FOR THE EASTERN
DISTRICT OF NEW YORK

PROOF OF CLAIM AND RELEASE

Deadline for Submission: September 21, 2017

IF YOU PURCHASED ALBANY MOLECULAR RESEARCH, INC. (“AMRI”) COMMON STOCK DURING THE PERIOD FROM AUGUST 5, 2014 THROUGH NOVEMBER 5, 2014, INCLUSIVE, (THE “SETTLEMENT CLASS PERIOD”), YOU ARE A “SETTLEMENT CLASS MEMBER” AND YOU MAY BE ENTITLED TO SHARE IN THE SETTLEMENT PROCEEDS.

IF YOU ARE A SETTLEMENT CLASS MEMBER, YOU MUST COMPLETE AND SUBMIT THIS FORM IN ORDER TO BE ELIGIBLE FOR ANY SETTLEMENT BENEFITS.

YOU MUST COMPLETE AND SIGN THIS PROOF OF CLAIM AND RELEASE (“PROOF OF CLAIM”) AND MAIL IT BY FIRST CLASS MAIL, POSTMARKED NO LATER THAN SEPTEMBER 21, 2017 TO STRATEGIC CLAIMS SERVICES, THE CLAIMS ADMINISTRATOR, AT THE FOLLOWING ADDRESS:

Albany Molecular Research, Inc. Litigation
c/o Strategic Claims Services
P.O. Box 230
600 N. Jackson St., Ste. 3
Media, PA 19063
Tel.: 866-274-4004
Fax: 610-565-7985
info@strategicclaims.net

YOUR FAILURE TO SUBMIT YOUR CLAIM BY SEPTEMBER 21, 2017 WILL SUBJECT YOUR CLAIM TO REJECTION AND PRECLUDE YOU FROM RECEIVING ANY MONEY IN CONNECTION WITH THE SETTLEMENT OF THIS ACTION. DO NOT MAIL OR DELIVER YOUR CLAIM TO THE COURT OR TO ANY OF THE PARTIES OR THEIR COUNSEL, AS ANY SUCH CLAIM WILL BE DEEMED NOT TO HAVE BEEN SUBMITTED. SUBMIT YOUR CLAIM ONLY TO THE CLAIMS ADMINISTRATOR.

CLAIMANT’S STATEMENT

1. I (we) purchased AMRI common stock and was (were) damaged thereby. (Do not submit this Proof of Claim if you did not purchase AMRI common stock during the designated Settlement Class Period).
2. By submitting this Proof of Claim, I (we) state that I (we) believe in good faith that I am (we are) a Settlement Class Member(s) as defined above and in the Notice of Pendency and Proposed Settlement of Class Action and Fairness Hearing (the “Notice”), or am (are) acting for such person(s); that I am (we are) not a Defendant in the Action or anyone excluded from the Settlement Class; that I (we) have read and understand the Notice; that I (we) believe that I am (we are) entitled to receive a share of the Net Settlement Fund, as defined in the Notice; that I (we) elect to participate in the proposed Settlement described in the Notice; and that I (we) have not filed a request for exclusion. (If you are acting in a representative capacity on behalf of a Settlement Class Member [e.g., as an executor, administrator, trustee, or other representative], you must submit evidence of your current authority to act on behalf of that Settlement Class Member. Such evidence would include, for example, letters testamentary, letters of administration, or a copy of the trust documents.)
3. I (we) consent to the jurisdiction of the Court with respect to all questions concerning the validity of this Proof of Claim. I (we) understand and agree that my (our) claim may be subject to investigation and discovery under the Federal Rules of Civil Procedure, provided that such investigation and discovery shall be limited to my (our) status as a Settlement Class Member(s) and the validity and

amount of my (our) claim. No discovery shall be allowed on the merits of the Action or Settlement in connection with processing of the Proof of Claim.

4. I (we) have set forth where requested below all relevant information with respect to each purchase of AMRI common stock during the period from August 5, 2014 through and including February 3, 2015, and each sale, if any, of such securities. I (we) agree to furnish additional information to the Claims Administrator to support this claim if requested to do so.
5. I (we) have enclosed photocopies of the stockbroker's confirmation slips, stockbroker's statements, or other documents evidencing each purchase, sale or retention of AMRI common stock listed below in support of my (our) claim. (IF ANY SUCH DOCUMENTS ARE NOT IN YOUR POSSESSION, PLEASE OBTAIN A COPY OR EQUIVALENT DOCUMENTS FROM YOUR BROKER BECAUSE THESE DOCUMENTS ARE NECESSARY TO PROVE AND PROCESS YOUR CLAIM.)
6. I (we) understand that the information contained in this Proof of Claim is subject to such verification as the Claims Administrator may request or as the Court may direct, and I (we) agree to cooperate in any such verification. (The information requested herein is designed to provide the minimum amount of information necessary to process most simple claims. The Claims Administrator may request additional information as required to efficiently and reliably calculate your Recognized Claim. In some cases, the Claims Administrator may condition acceptance of the claim based upon the production of additional information, including, where applicable, information concerning transactions in any derivatives securities such as options.)
7. Upon the occurrence of the Court's approval of the Settlement, as detailed in the Notice, I (we) agree and acknowledge that my (our) signature(s) hereto shall effect and constitute a full and complete release, remise and discharge by me (us) and my (our) current, past and future personal representatives, immediate family, trustees, heirs, executors, administrators, parent entities, associates, affiliates, predecessors, successors and assigns, and any other person or entity claiming (now or in the future) to be acting on behalf of any of them, of all of the Released Claims (as defined in the Stipulation) against each of the Released Persons (as defined in the Stipulation).
8. NOTICE REGARDING ELECTRONIC FILES: Certain claimants with large numbers of transactions may request, or may be requested, to submit information regarding their transactions in electronic files. All Claimants MUST submit a manually signed paper Proof of Claim form listing all their transactions whether or not they also submit electronic copies. If you wish to file your claim electronically, you must contact the Claims Administrator at 1-866-274-4004 or visit their website at www.strategicclaims.net to obtain the required file layout. No electronic files will be considered to have been properly submitted unless the Claims Administrator issues to the Claimant a written acknowledgment of receipt and acceptance of electronically submitted data.

I. CLAIMANT INFORMATION

Name		
Address		
City	State	ZIP
Foreign Provence	Foreign Country	
Day Phone	Evening Phone	
Email		
Social Security Number (for individuals)	OR	Taxpayer Identification Number (for estates, trusts, corporations, etc.)

II. SCHEDULE OF TRANSACTIONS IN AMRI COMMON STOCK

Beginning Holdings:

A. State the total number of shares of AMRI common stock owned at the close of trading on August 4, 2014, long or short (*must be documented*).

--

Purchases:

B. Separately list each and every open market purchase of AMRI common stock during the period from August 5, 2014 through and including February 3, 2015, provide the following information (*must be documented*):

Trade Date (List Chronologically) (Month/Day/Year)	Number of Shares Purchased	Price per Share	Total Cost (Excluding Commissions, Taxes, and Fees)

Sales:

C. Separately list each and every sale of AMRI common stock during the period from August 5, 2014 through and including February 3, 2015, and provide the following information (*must be documented*):

Trade Date (List Chronologically) (Month/Day/Year)	Number of Shares Sold	Price per Share	Amount Received (Excluding Commissions, Taxes, and Fees)

Ending Holdings:

D. State the total number of shares of AMRI common stock owned at the close of trading on February 3, 2015, long or short (*must be documented*).

--

If additional space is needed, attach separate, numbered sheets, giving all required information, substantially in the same format, and print your name and Social Security or Taxpayer Identification number at the top of each sheet.

III. SUBSTITUTE FORM W-9

Request for Taxpayer Identification Number:

Enter taxpayer identification number below for the Beneficial Owner(s). For most individuals, this is your Social Security Number. The Internal Revenue Service (“I.R.S.”) requires such taxpayer identification number. If you fail to provide this information, your claim may be rejected.

Social Security Number (for individuals)	or	Taxpayer Identification Number (for estates, trusts, corporations, etc.)

IV. CERTIFICATION

I (We) certify that I am (we are) NOT subject to backup withholding under the provisions of Section 3406 (a)(1)(c) of the Internal Revenue Code because: (a) I am (We are) exempt from backup withholding, or (b) I (We) have not been notified by the I.R.S. that I am (we are) subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the I.R.S. has notified me (us) that I am (we are) no longer subject to backup withholding.

NOTE: If you have been notified by the I.R.S. that you are subject to backup withholding, please strike out the language that you are not subject to backup withholding in the certification above.

UNDER THE PENALTIES OF PERJURY UNDER THE LAWS OF THE UNITED STATES, I (WE) CERTIFY THAT ALL OF THE INFORMATION I (WE) PROVIDED ON THIS PROOF OF CLAIM AND RELEASE FORM IS TRUE, CORRECT AND COMPLETE.

Signature of Claimant (If this claim is being made on behalf of Joint Claimants, then each must sign):

(Signature)

(Signature)

(Capacity of person(s) signing, e.g. beneficial purchaser(s), executor, administrator, trustee, etc.)

Check here if proof of authority to file is enclosed.
(See Item 2 under Claimant's Statement)

Date: _____

THIS PROOF OF CLAIM MUST BE POSTMARKED NO LATER THAN SEPTEMBER 21, 2017 AND MUST BE MAILED TO:

Albany Molecular Research, Inc. Litigation
c/o Strategic Claims Services
P.O. Box 230
600 N. Jackson St., Ste. 3
Media, PA 19063
Tel.: 866-274-4004
Fax: 610-565-7985
info@strategicclaims.net

A Proof of Claim received by the Claims Administrator shall be deemed to have been submitted when posted, if mailed by September 21, 2017 and if a postmark is indicated on the envelope and it is mailed first class and addressed in accordance with the above instructions. In all other cases, a Proof of Claim shall be deemed to have been submitted when actually received by the Claims Administrator.

You should be aware that it will take a significant amount of time to process fully all of the Proofs of Claim and to administer the Settlement. This work will be completed as promptly as time permits, given the need to investigate and tabulate each Proof of Claim. Please notify the Claims Administrator of any change of address.

REMINDER CHECKLIST

- Please be sure to sign this Proof of Claim on page 19. If this Proof of Claim is submitted on behalf of joint claimants, then both claimants must sign.
- Please remember to attach supporting documents. Do NOT send any stock certificates. Keep copies of everything you submit.
- Do NOT use highlighter on the Proof of Claim or any supporting documents.
- If you move after submitting this Proof of Claim, please notify the Claims Administrator of the change in your address.

Albany Molecular Research, Inc. Litigation
c/o Strategic Claims Services
600 N. Jackson St., Ste. 3
Media, PA 19063

IMPORTANT LEGAL DOCUMENT – PLEASE FORWARD